BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer and BioNTech miss on influenza. Pfizer and BioNTech enrolled more than 8,000 healthy adults into a phase 3 trial with an mRNA vaccine candidate built to protect against influenza and COVID-19.

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

In November, American pharmaceutical giant Pfizer and its German partner BioNTech began enrolling child volunteers aged 12 to 17 in the Phase 2/3 trials of their two-dose COVID-19 vaccine.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162b2 mRNA ...

Pfizer (PFE -1.64%) and BioNTech (BNTX -1.15%) recently fell behind in their race with Moderna (MRNA -1.60%) to develop new combination shots that could be worth billions in annual sales.

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages including the XFG and NB.1.8.1 variants1 compared to 2024-20 ...